What were the key takeaways from Lisata Therapeutics's earnings call?

What is Lisata Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from Lisata Therapeutics’s earnings call?

What is the market's earnings forecast for Lisata Therapeutics next quarter?

What is the revenue and EPS growth rate for Lisata Therapeutics year over year?

What guidance did Lisata Therapeutics's management provide for the next earnings period?

What factors drove the changes in Lisata Therapeutics's revenue and profit?

Did Lisata Therapeutics beat or miss consensus estimates last quarter?

- **Financial Stability**: Operating expenses down 17.3% YoY to $4.4 million; $19M cash runway to Q1 2027.
- **Clinical Momentum**: ASCEND trial Cohort A shows 4 complete responses; CENDIFOX pancreatic cancer resection rate 50%.
- **Strategic Expansion**: Catalent ADC partnership with preclinical success; GATC AI drug discovery alliance identifies 2026 candidates.
- **Phase III Challenges**: ASCEND Phase III funding requires pharma partners; stock underperformance despite positive data.


**【CEO Summary Section】**
- Announced strategic alliance with GATC Health to leverage AI for drug discovery and new indications.
- Entered nonexclusive license agreement with Catalent for certepetide use in ADCs, with preclinical data showing enhanced tumor targeting.
- Anticipated Phase III trial for ASCEND contingent on capital acquisition, with FDA-endorsed protocol finalized.
- GBM trial enrollment on track at 2/3 of target 30 patients, with completion expected in 2026.

**【CFO Financial Commentary】**
- Q3 2025 operating expenses: $4.4 million (17.3% YoY decrease), driven by R&D (-22.9%) and G&A (-12.1%) savings.
- Net loss of $4.2 million; cash balance $19 million, supporting operations into Q1 2027.
- Expense reductions achieved through optimized trial costs, consulting cuts, and staff reductions.

**【CMO Clinical Update】**
- ASCEND trial: Cohort A (95 pts) showed 4 complete responses vs. 0 in control; Cohort B (63 pts) demonstrated improved PFS and OS. Final data Q1 2026.
- CENDIFOX: 50% R0 resection rate in pancreatic cancer, 70% pathological response, 60% 2-year OS. Additional data pending.
- iLSTA: Combining certepetide with durvalumab in pancreatic cancer showed enhanced immune response; final data Q1 2026.
- Qilu Pharmaceutical's China trial for metastatic pancreatic cancer nearing completion, data expected 2026-2027.

**【Q&A Highlights】**
- CENDIFOX next data release timing uncertain due to investigator control; GBM trial enrollment 2/3 complete.
- Cash runway excludes Phase III costs; seeking pharma partners to share funding burden.
- Stock underperformance attributed to macro biotech headwinds and limited trading float.
- Exploring nonexclusive licensing to expand certepetide applications, with multiple candidates in pipeline.


LSTA

LSTA fundamentals

You can ask Aime